CA Patent

CA2402637C — Valve for osmotic devices

Assigned to Intarcia Therapeutics Inc · Expires 2007-04-10 · 19y expired

What this patent protects

An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule having a beneficial agent reservoir, an osmotic agent which expands on contact with fluid imbibed through a permeable membrane retained by the implant capsule, a delivery port, an…

USPTO Abstract

An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule having a beneficial agent reservoir, an osmotic agent which expands on contact with fluid imbibed through a permeable membrane retained by the implant capsule, a delivery port, and a valve for opening and closing the delivery port. When the osmotic agent expands, a pressure is exerted against a separating member positioned between the beneficial agent reservoir and the osmotic agent. The separating member moves within the capsule, thereby forcing the valve to mov e a distance such that the beneficial agent can exit the reservoir through the delivery port.

Drugs covered by this patent

Patent Metadata

Patent number
CA2402637C
Jurisdiction
CA
Classification
Expires
2007-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Intarcia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.